Prof Solange Peters (Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland), Dr Federico Cappuzzo (National Cancer Institute Regina Elena, Rome, Italy), Dr Antonio Passaro (European Institute of Oncology, Milan, Italy) and Prof Sanjay Popat (The Royal Marsden Hospital, London, UK) discuss the latest in the treatment of lung cancer from new data reported at ESMO 2020.
They give their expert opinion on the following topics and discuss both their experience so far and plans for the future of clinical practice.
• Lorlatinib vs crizotinib in the first-line treatment of patients with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study
• Osimertinib adjuvant therapy in patients with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
• An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK)
• IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
• EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
• WJOG @Be Study: A Phase II Study of Atezolizumab (Atez) With Bevacizumab (Bev) for Non-Squamous (Sq) Non-Small-Cell Lung Cancer (NSCLC) with High PD-L1 Expression
• Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC
• Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy – results from the ETOP/IFCT 4-12 STIMULI trial
